International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials

Vaccine
T Christopher MastJohn W Shiver

Abstract

Replication-defective adenoviruses have been utilized as candidate HIV vaccine vectors. Few studies have described the international epidemiology of pre-existing immunity to adenoviruses. We enrolled 1904 participants in a cross-sectional serological survey at seven sites in Africa, Brazil, and Thailand to assess neutralizing antibodies (NA) for adenovirus types Ad5, Ad6, Ad26 and Ad36. Clinical trial samples were used to assess NA titers from the US and Europe. The proportions of participants that were negative were 14.8% (Ad5), 31.5% (Ad6); 41.2% (Ad26) and 53.6% (Ad36). Adenovirus NA titers varied by geographic location and were higher in non-US and non-European settings, especially Thailand. In multivariate logistic regression analysis, geographic setting (non-US and non-European settings) was statistically significantly associated with having higher Ad5 titers; participants from Thailand had the highest odds of having high Ad5 titers (adjusted OR=3.53, 95% CI: 2.24, 5.57). Regardless of location, titers of Ad5NA were the highest and Ad36 NA were the lowest. Coincident Ad5/6 titers were lower than either Ad5 or Ad6 titers alone. Understanding pre-existing immunity to candidate vaccine vectors may contribute to the evaluatio...Continue Reading

References

Aug 1, 1982·The Journal of Hygiene·E D'AmbrosioM Midulla
Sep 22, 1999·Gene Therapy·N ChirmuleJ Wilson
May 7, 2002·The Journal of Infectious Diseases·Martina SesterHans Köhler
Sep 14, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Shellie A Kolavic-GrayBruce L Innis
Dec 13, 2002·Journal of Virology·Zhi-yong YangGary J Nabel
Jan 30, 2004·Annual Review of Medicine·John W Shiver, Emilio A Emini
Sep 29, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Nia Tatsis, Hildegund C J Ertl
Mar 12, 2005·Human Gene Therapy·Dan H Barouch, Gary J Nabel
Oct 6, 2006·Journal of Clinical Microbiology·Anna R ThornerDan H Barouch
Jan 16, 2008·The Journal of Experimental Medicine·Rafick-Pierre Sekaly
Apr 25, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Frances H PriddyUNKNOWN Merck V520-016 Study Group
Nov 8, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Erin K QuirkMichael N Robertson
Dec 26, 2008·AIDS Research and Human Retroviruses·Clayton D HarroUNKNOWN Merck V520-007/012 Study Teams
Aug 21, 2009·Parasite Immunology·K J Limbach, T L Richie

❮ Previous
Next ❯

Citations

Jun 4, 2015·Emerging Microbes & Infections·Xiang WangDongming Zhou
Mar 4, 2014·Human Gene Therapy·Dragomira MajhenJerome Custers
Mar 19, 2014·Human Gene Therapy·Zenaido T CamachoEric A Weaver
Oct 29, 2010·International Journal of Hypertension·Sam L StephenSreenivasan Ponnambalam
Dec 29, 2011·The Journal of Clinical Investigation·Nelson L Michael
Jul 3, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Jin Huk Choi, Maria A Croyle
Aug 30, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Lynda CoughlanAndrew H Baker
Apr 3, 2010·Cancer Immunology, Immunotherapy : CII·Elizabeth S GabitzschFrank R Jones
Jul 23, 2013·Retrovirology·Torben SchiffnerLucy Dorrell
Sep 17, 2011·Expert Review of Vaccines·Jennifer D BassettJonathan L Bramson
Aug 3, 2011·Expert Review of Vaccines·Merlin Robb
May 9, 2012·Expert Opinion on Biological Therapy·Thomas HoenenHeinz Feldmann
Dec 23, 2014·Expert Opinion on Biological Therapy·Mohan Babu Appaiahgari, Sudhanshu Vrati
Feb 5, 2015·Expert Opinion on Biological Therapy·Rachael T Richardson, Patrick J Atkinson
Jul 28, 2010·Biologicals : Journal of the International Association of Biological Standardization·Béatris MastelicPaul-Henri Lambert
Jul 8, 2015·AIDS Research and Human Retroviruses·Daniela Santoro RosaEdecio Cunha-Neto
Jun 19, 2013·Immunological Reviews·Kathryn E Stephenson, Dan H Barouch
Sep 10, 2015·Reviews in Medical Virology·Jameson D VossNikhil V Dhurandhar
Apr 12, 2012·Biochemical and Biophysical Research Communications·Bin YuXianghui Yu
Jun 2, 2015·Journal of Virological Methods·Minna YlihärsiläMatti Waris
Apr 16, 2015·Human Vaccines & Immunotherapeutics·Kui XiangSun Maosheng
Mar 12, 2015·Human Gene Therapy·Rachel S DakinAndrew H Baker
Nov 28, 2013·Human Vaccines & Immunotherapeutics·Eric A Weaver

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.